View Future GrowthBio Plus 과거 순이익 실적과거 기준 점검 2/6Bio Plus은 연평균 4.8%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 4.2% 증가했습니다. 매출은 연평균 20.5%의 비율로 증가했습니다. Bio Plus의 자기자본이익률은 9.8%이고 순이익률은 14.8%입니다.핵심 정보4.76%순이익 성장률2.38%주당순이익(EPS) 성장률Medical Equipment 산업 성장률22.66%매출 성장률20.46%자기자본이익률9.78%순이익률14.82%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...분석 기사 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...분석 기사 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.모든 업데이트 보기Recent updatesNew Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin).Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.2% over the past three years.공시 • Mar 10Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,550, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 35% over the past three years.New Risk • Feb 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.0% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (17% net profit margin).분석 기사 • Jan 30Is Bio Plus (KOSDAQ:099430) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).분석 기사 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...분석 기사 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공시 • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Medical Equipment industry in South Korea. Total loss to shareholders of 9.0% over the past three years.New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (18% net profit margin).분석 기사 • Aug 18Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jul 22Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't IdealThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...분석 기사 • May 09What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling YouBio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders have had their patience rewarded with a 26% share price jump in the...Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩8,020, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 8.8% over the past three years.분석 기사 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...New Risk • Mar 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 39% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (68% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).공시 • Feb 28Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩7,170, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 16% over the past three years.분석 기사 • Feb 14Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Jan 07Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch UpDespite an already strong run, Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have been powering on, with a gain of 30% in...Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).분석 기사 • Dec 15Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,880, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past three years.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (69% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change).분석 기사 • Nov 23Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For ExitBio Plus Co., Ltd's ( KOSDAQ:099430 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell right...Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,560, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years.공시 • Aug 02Bio Plus Co., Ltd announced that it has received KRW 60 billion in fundingOn July 31, 2024, Bio Plus Co., Ltd, closed the transaction.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (54% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).분석 기사 • Jul 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have had a really impressive month, gaining 29% after a shaky period...Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,450, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.3% over the past year.분석 기사 • Jul 05The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire ConfidenceWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...공시 • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.Buy Or Sell Opportunity • Jun 10Now 22% overvaluedOver the last 90 days, the stock has fallen 33% to ₩4,580. The fair value is estimated to be ₩3,756, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%.분석 기사 • Jun 08More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders that were waiting for something to happen have been dealt a blow with...Valuation Update With 7 Day Price Move • May 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩5,180, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 19% over the past year.분석 기사 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).Buying Opportunity • Oct 19Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be ₩8,126, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Earnings per share has grown by 92%. Revenue is forecast to grow by 84% in 2 years. Earnings is forecast to grow by 63% in the next 2 years.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,870, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩7,559 per share.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,370, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩4,098 per share.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,550, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩11,285 per share.Price Target Changed • Dec 15Price target increased to ₩9,750Up from ₩8,917, the current price target is an average from 3 analysts. New target price is 33% above last closing price of ₩7,330. Stock is up 16% over the past year. The company is forecast to post earnings per share of ₩362 for next year compared to ₩207 last year.Price Target Changed • Nov 16Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 34% above last closing price of ₩28,700. Stock is up 18% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩31,100, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩46,800 per share.Price Target Changed • Nov 02Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₩26,750. Stock is down 0.6% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩24,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩40,006 per share.공시 • Oct 07BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in fundingBioPlus Co., Ltd. announced a private placement of 690,845 registered non-voting redeemable convertible preferred shares at issue price of KRW 28,950 per share for gross proceeds of KRW 19,999,962,750? on October 6, 2022. The transaction will include participation from Lindman - Woori Technology Finance Fund No. 13 for 69,084 shares, Lindman Innovation Growth Private Equity Joint Venture for 345,423 shares, and Lindman Asia Fund No. 16 for 276,338 shares. The shares carry rate of interest of 10% per annum. The shares to be issued shall have a hold period of 1 year from the closing of the transaction. The repayment period is from April 25, 2025 to October 24, 2032. The shares are convertible into 690,845 shares of the company from January 25, 2023 to October 24, 2032. The transaction is expected to close on October 24, 2022. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩28,450, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩43,793 per share.매출 및 비용 세부 내역Bio Plus가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A099430 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2694,42413,99643,6723,39331 Dec 2590,89615,00139,5543,39430 Sep 2596,80216,04933,3602,86130 Jun 2589,16316,20926,7112,44931 Mar 2579,77919,60419,8841,98631 Dec 2466,41014,15115,7221,47730 Sep 2453,47917,79912,3941,36730 Jun 2454,58120,01310,6521,26631 Mar 2462,24821,78310,1181,31731 Dec 2365,04325,5819,1951,16530 Sep 2365,36824,8808,1921,19530 Jun 2361,97624,6367,1301,20531 Mar 2357,10322,6686,3671,08931 Dec 2256,71921,1376,2691,08130 Sep 2251,35318,3945,43590830 Jun 2245,28212,2175,33061831 Mar 2240,61211,2695,22254331 Dec 2137,41810,7254,60743530 Sep 2135,08410,3214,80746230 Jun 2134,57415,1824,50147531 Mar 2128,61711,6983,83034931 Dec 2024,3679,7033,76627630 Sep 2020,5518,2513,40629230 Jun 2016,6375,5213,41627031 Mar 2017,4076,0253,58814631 Dec 1917,0215,6233,61721530 Sep 1914,1613,7483,115030 Jun 1913,4243,5672,872031 Mar 1912,2132,9822,6039031 Dec 1811,0382,3712,291031 Dec 173,4893761,1130양질의 수익: A099430는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A099430의 현재 순 이익률 (14.8%)은 지난해 (24.6%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A099430의 수익은 지난 5년 동안 연평균 4.8% 증가했습니다.성장 가속화: A099430은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: A099430은 지난 1년 동안 수익이 감소(-28.6%)하여 Medical Equipment 업계 평균(23.1%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: A099430의 자본 수익률(9.8%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 19:37종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bio Plus Co., Ltd는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hyung Soo KimHanwha Investment & Securities Co., Ltd.Junghyun KimKyobo Securities Co., LtdJaehee WonShinhan Investment Corp.1명의 분석가 더 보기
분석 기사 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...
분석 기사 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...
분석 기사 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.
New Risk • May 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin).
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩6,100, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 21x in the Medical Equipment industry in South Korea. Total loss to shareholders of 2.2% over the past three years.
공시 • Mar 10Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026Bio Plus Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩4,550, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 35% over the past three years.
New Risk • Feb 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.0% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (17% net profit margin).
분석 기사 • Jan 30Is Bio Plus (KOSDAQ:099430) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 13 April 2026. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%).
분석 기사 • Nov 27We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish EarningsBio Plus Co., Ltd's ( KOSDAQ:099430 ) recent weak earnings report didn't cause a big stock movement. Our analysis...
분석 기사 • Nov 10Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00Bio Plus Co., Ltd ( KOSDAQ:099430 ) will pay a dividend of ₩50.00 on the 13th of April. The dividend yield is 0.8...
Declared Dividend • Nov 08Dividend of ₩50.00 announcedDividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 13th April 2026 Dividend yield will be 0.8%, which is lower than the industry average of 1.8%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 13% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공시 • Nov 07Bio Plus Co., Ltd announces Annual dividend, payable on April 13, 2026Bio Plus Co., Ltd announced Annual dividend of KRW 50.0000 per share payable on April 13, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Valuation Update With 7 Day Price Move • Sep 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 24x in the Medical Equipment industry in South Korea. Total loss to shareholders of 9.0% over the past three years.
New Risk • Sep 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (18% net profit margin).
분석 기사 • Aug 18Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Jul 22Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't IdealThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
분석 기사 • May 09What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling YouBio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders have had their patience rewarded with a 26% share price jump in the...
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₩8,020, the stock trades at a trailing P/E ratio of 32.9x. Average trailing P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 8.8% over the past three years.
분석 기사 • Mar 31Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You ThinkThe subdued market reaction suggests that Bio Plus Co., Ltd's ( KOSDAQ:099430 ) recent earnings didn't contain any...
New Risk • Mar 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 39% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (68% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (21% net profit margin).
공시 • Feb 28Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025Bio Plus Co., Ltd, Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩7,170, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total returns to shareholders of 16% over the past three years.
분석 기사 • Feb 14Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jan 07Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch UpDespite an already strong run, Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have been powering on, with a gain of 30% in...
Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%).
분석 기사 • Dec 15Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,880, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past three years.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (69% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.3% average weekly change).
분석 기사 • Nov 23Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For ExitBio Plus Co., Ltd's ( KOSDAQ:099430 ) price-to-earnings (or "P/E") ratio of 14.9x might make it look like a sell right...
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,560, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 12x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years.
공시 • Aug 02Bio Plus Co., Ltd announced that it has received KRW 60 billion in fundingOn July 31, 2024, Bio Plus Co., Ltd, closed the transaction.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (54% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).
분석 기사 • Jul 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shares have had a really impressive month, gaining 29% after a shaky period...
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩6,450, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 4.3% over the past year.
분석 기사 • Jul 05The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire ConfidenceWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
공시 • Jun 11Bio Plus Co., Ltd (KOSDAQ:A099430) announces an Equity Buyback for KRW 5,000 million worth of its shares.Bio Plus Co., Ltd (KOSDAQ:A099430) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares, pursuant to a contract with Korea Investment & Securities Co.,Ltd. The purpose of the program is to stabilize stock price and to enhance the shareholder value. The program will expire on December 10, 2024. As of June 9, 2024, the company had 743,436 shares in treasury within scope available for dividend and had no shares in treasury under other capacities.
Buy Or Sell Opportunity • Jun 10Now 22% overvaluedOver the last 90 days, the stock has fallen 33% to ₩4,580. The fair value is estimated to be ₩3,756, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 25%.
분석 기사 • Jun 08More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%Bio Plus Co., Ltd ( KOSDAQ:099430 ) shareholders that were waiting for something to happen have been dealt a blow with...
Valuation Update With 7 Day Price Move • May 17Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩5,180, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total loss to shareholders of 19% over the past year.
분석 기사 • Mar 26Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong EarningsBio Plus Co., Ltd ( KOSDAQ:099430 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Reported Earnings • Mar 24Full year 2023 earnings released: EPS: ₩445 (vs ₩372 in FY 2022)Full year 2023 results: EPS: ₩445 (up from ₩372 in FY 2022). Revenue: ₩65.0b (up 15% from FY 2022). Net income: ₩25.6b (up 21% from FY 2022). Profit margin: 39% (up from 37% in FY 2022). The increase in margin was driven by higher revenue.
Upcoming Dividend • Dec 20Upcoming dividend of ₩70.00 per share at 1.0% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).
Buying Opportunity • Oct 19Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be ₩8,126, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Earnings per share has grown by 92%. Revenue is forecast to grow by 84% in 2 years. Earnings is forecast to grow by 63% in the next 2 years.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩8,870, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Medical Equipment industry in South Korea. Total returns to shareholders of 11% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩7,559 per share.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,370, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 12% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩4,098 per share.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,550, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩11,285 per share.
Price Target Changed • Dec 15Price target increased to ₩9,750Up from ₩8,917, the current price target is an average from 3 analysts. New target price is 33% above last closing price of ₩7,330. Stock is up 16% over the past year. The company is forecast to post earnings per share of ₩362 for next year compared to ₩207 last year.
Price Target Changed • Nov 16Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 34% above last closing price of ₩28,700. Stock is up 18% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩31,100, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩46,800 per share.
Price Target Changed • Nov 02Price target increased to ₩38,500Up from ₩35,667, the current price target is an average from 2 analysts. New target price is 44% above last closing price of ₩26,750. Stock is down 0.6% over the past year. The company is forecast to post earnings per share of ₩1,493 for next year compared to ₩828 last year.
Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₩24,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩40,006 per share.
공시 • Oct 07BioPlus Co., Ltd. announced that it expects to receive KRW 19.99996275 billion in fundingBioPlus Co., Ltd. announced a private placement of 690,845 registered non-voting redeemable convertible preferred shares at issue price of KRW 28,950 per share for gross proceeds of KRW 19,999,962,750? on October 6, 2022. The transaction will include participation from Lindman - Woori Technology Finance Fund No. 13 for 69,084 shares, Lindman Innovation Growth Private Equity Joint Venture for 345,423 shares, and Lindman Asia Fund No. 16 for 276,338 shares. The shares carry rate of interest of 10% per annum. The shares to be issued shall have a hold period of 1 year from the closing of the transaction. The repayment period is from April 25, 2025 to October 24, 2032. The shares are convertible into 690,845 shares of the company from January 25, 2023 to October 24, 2032. The transaction is expected to close on October 24, 2022. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Jul 07Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩28,450, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Simply Wall St's valuation model estimates the intrinsic value at ₩43,793 per share.